The NUT Carcinoma Specialty at the Chongqing University Three Gorges Hospital was officially established in 2023, making it the first and only specialized department dedicated to NUT Carcinoma in China. It serves as a treatment platform for patients nationwide. This specialty integrates tumor clinical care, research, prevention, and education, functioning as a comprehensive department. Collaborating with the Clinical Research Center, Early Cancer Diagnosis and Treatment Center, Translational Medicine Research Center, Molecular Pathology Center, and Medical Data Center, it undertakes research on NUT carcinoma prevention, early screening, diagnosis, and treatment. Maintaining partnerships with leading domestic and international research institutions, it boasts extensive resources, advanced technology, and high academic influence, enabling comprehensive treatment for NUT Carcinoma.

1. In August 2020, our team initiated the clinical Phase I trial of NHWD-870 HCl;

2. In January 2023, the team established the first specialized clinic for NUT midline carcinoma (the only one of its kind in China), with the applicant appointed as the director of the clinic.

3. In June 2023, China established the NUT Carcinoma Gene Diagnosis Working Group under the Tumor Gene Diagnosis Committee of the Chinese Anti-Cancer Association, with Professor Yin serving as the group leader.

4. In October 2023, the team released the first domestic "Expert Consensus on Diagnosis and Treatment of NUT Carcinoma (2023 Edition)."

5. In April 2024, the clinical Phase II trial of NHWD-870 HCl targeting NUT carcinoma was initiated.